With any therapy for early prostate cancer, control must be evaluated with a view to toxicities. Brachytherapy may be associated with urethral and rectal toxicity and erectile impotence. Patients with large glands or significant symptoms before treatment are at greatest risk. Long-term toxicity can be minimized by understanding the tolerance of the normal tissues and meticulous placement of the radioactive seeds.